Clinical data of COVID-19 infected patients

Objectives

This study aimed to evaluate the clinical efficacy of Paxlovid in patients hospitalized with severe/critical COVID-19.

Methods

Data were acquired from patients with severe/critical COVID-19 diagnosed between December 2022 and January 2023 at a medical center in China. Patients were divided into the Paxlovid treatment group and the conventional treatment group. The association between Paxlovid and all-cause mortality of patients during hospitalization was evaluated using the COX regression model and inverse probability weighting method, respectively. The secondary endpoint was the improvement in patients’ lung imaging findings 1 week later. The odds ratio (OR) was estimated using logistic regression.

Results

A total of 158 eligible patients were enrolled, including 50 in-hospital deaths (50/98) in the Paxlovid group and 28 (28/60) in the conventional treatment group. The corrected hazard ratio for death was 0.51 (95% CI: 0.28–0.94, p = 0.031) and the inverse probability-weighted hazard ratio was 0.42 (95% CI: 0.24–0.75). The secondary endpoint analysis revealed that Paxlovid was associated with improved lung imaging findings 1 week later (adjusted OR: 0.35, 95% CI: 0.16–0.77).

Conclusion

Treatment with Paxlovid is associated with a significantly reduced risk of death and improved lung imaging findings in patients with severe/critical COVID-19.